Elagolix + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Polycystic Ovary Syndrome
Conditions
Polycystic Ovary Syndrome
Trial Timeline
Aug 12, 2019 → Feb 10, 2021
NCT ID
NCT03951077About Elagolix + Placebo
Elagolix + Placebo is a phase 2 stage product being developed by AbbVie for Polycystic Ovary Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT03951077. Target conditions include Polycystic Ovary Syndrome.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03951077 | Phase 2 | Completed |
| NCT03886220 | Approved | Completed |
| NCT00619866 | Phase 2 | Completed |
Competing Products
20 competing products in Polycystic Ovary Syndrome